Medical releases
Medical releases
Results 1 – 10 of 140 for LYNPARZA (3.82 seconds)
Oncology
Oncology
Meet AZN management at ASCO2020
Meet AZN management at ASCO2020
Lynparza approved in the EU for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Lynparza approved in the EU for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
AstraZeneca and Foundation Medicine enter strategic collaboration for Lynparza companion diagnostic assay
AstraZeneca and Foundation Medicine enter strategic collaboration for Lynparza companion diagnostic assay
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Lynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer
Lynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer